(-0.86%) 5 028.15 points
(-1.26%) 37 978 points
(-1.26%) 15 515 points
(-0.29%) $82.57
(-0.24%) $1.649
(0.18%) $2 342.50
(-0.15%) $27.31
(0.33%) $918.85
(-0.15%) $0.933
(0.05%) $10.99
(-0.24%) $0.800
(-0.09%) $92.24
Live Chart Being Loaded With Signals
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight...
Stats | |
---|---|
Today's Volume | 692 760 |
Average Volume | 314 435 |
Market Cap | 31.65M |
EPS | €0 ( 2024-04-08 ) |
Next earnings date | ( €0 ) 2024-05-15 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.610 |
ATR14 | €0.00600 (0.92%) |
Volume Correlation
Poxel SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Poxel SA Correlation - Currency/Commodity
Poxel SA Financials
Annual | 2023 |
Revenue: | €1.98M |
Gross Profit: | €1.98M (100.00 %) |
EPS: | €0 |
Q4 | 2023 |
Revenue: | €1.03M |
Gross Profit: | €1.03M (100.00 %) |
EPS: | €0 |
Q2 | 2023 |
Revenue: | €955 000 |
Gross Profit: | €-16.92M (-1 771.94 %) |
EPS: | €-0.830 |
Q4 | 2022 |
Revenue: | €591 000 |
Gross Profit: | €-272 000 (-46.02 %) |
EPS: | €-0.620 |
Financial Reports:
No articles found.
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators